Reporter brief
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Retrospective design cannot establish causation or confirm that formulation differences caused observed blood level variations, as confounding factors were not controlled. The study does not report whether different blood levels translated to differences in clinical outcomes or longevity effects. Sample size and effect sizes were not reported, limiting assessment of statistical reliability or clinical significance of any differences found.
Study design and sample
Observational; Human.
normative aging individuals
- Design
- Observational
- Sample
- —
- Journal
- AgelessRx
- Published
- Aug 13, 2024
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.